Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutational burden and immune recognition of gliomas.

Current opinion in oncology - 1 Nov 2021

Prost Diego, Bielle Franck, Ligon Keith L, Touat Mehdi

Abstract excerpt

PURPOSE OF REVIEW: Recent evidence suggests high tumor mutational burden (TMB-H) as a predictor of response to immune checkpoint blockade (ICB) in cancer. However, results in TMB-H gliomas have been inconsistent. In this article, we discuss the main pathways leading to TMB-H in glioma and how these might affect immunotherapy response. RECENT FINDINGS: Recent characterization of TMB-H gliomas showed that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Glioma
Share to Immune Checkpoint Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Predictive Value of Tests

Share to Randomized Controlled Trials as Topic

Source

Identifiers

PMID: 34651608
DOI: 10.1097/CCO.0000000000000787

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutational burden and immune recognition of gliomas.PMID 34651608Read ↗

Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy.Semantic proximity Read ↗

Hypermutation as a Potential Predictive Biomarker of Immunotherapy Efficacy in High-Grade Gliomas: A Broken Dream?Semantic proximity Read ↗

Mechanisms and therapeutic implications of hypermutation in gliomas.Semantic proximity Read ↗

Potential of IDH mutations as immunotherapeutic targets in gliomas: a review and meta-analysis.Semantic proximity Read ↗

The Temozolomide Mutational Signature: Mechanisms, Clinical Implications, and Therapeutic Opportunities in Primary Brain Tumor Management.Semantic proximity Read ↗

Tumor Mutational Burden is Associated with Poor Outcomes in Diffuse Glioma.Semantic proximity Read ↗

Hypermutations in gliomas: a potential immunotherapy target.Semantic proximity Read ↗

Tumor mutational burden is associated with poor outcomes in diffuse glioma.Semantic proximity Read ↗

IDH mutation, glioma immunogenicity, and therapeutic challenge of primary mismatch repair deficient IDH-mutant astrocytoma PMMRDIA: a systematic review.Semantic proximity Read ↗

Tumor Mutation Burden, Expressed Neoantigens and the Immune Microenvironment in Diffuse GliomasSemantic proximity Read ↗

The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in GliomasSemantic proximity Read ↗

Immune profiling of gliomas reveals a connection with Tau function and the tumor vasculatureSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.